Clinical trial
A Study to Prevent Rebleeding After Initial Successful Primary Endoscopic…
NCT00251979 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00251979 |
|---|---|
| Title | A Study to Prevent Rebleeding After Initial Successful Primary Endoscopic Haemostasis of a Bleeding Peptic Ulcer |
| Official title | A Randomised, Double-blind, Parallel-group, Placebo Controlled Study of Esomeprazole i.v. (Bolus Infusion of 80 mg Followed by a Continuous Infusion of 8 mg Per Hour) Administered for 72 Hours to Assess Prevention of Rebleeding in Subjects That Have Undergone Successful Primary Endoscopic… |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Gastrointestinal Hemorrhage |
| Intervention type | Drug |
| Interventions | Esomeprazole |
| Enrollment | 1,312 |
| Start date | Oct 1, 2005 |
| Primary completion | Dec 1, 2007 |
| Completion | Dec 1, 2007 |
| First posted | Nov 11, 2005 |
| Last update posted | Jun 17, 2011 |
| Countries | Austria, Denmark, Finland, France, Germany, Greece, Hong Kong, Netherlands, Norway, Romania, Russia, South Africa and 4 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: